In 141 people aged 6–35 with newly diagnosed type 1 diabetes, low-dose IL-2 did not preserve β-cell function vs placebo: 12-month C-peptide AUC did not differ (geometric mean ratio 1.06; p=0.85), despite clear Treg expansion.
RCTn = 141
Rosenzwajg et al. Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial